Skip to content
Trial Eligibility
Menu

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

NCT06542757

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to assess the impact of this MR-guided radiotherapy on tumor control of the dominant intraprostatic lesion among patients with intermediate risk prostate cancer.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Prostate Cancer

Eligibility basics and study details

Study type
Interventional
Phase
Not applicable
Ages
18 years and older
Sex
Male
Healthy volunteers
Not accepted
Sponsor
NYU Langone Health
Last updated on ClinicalTrials.gov
March 11, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New York · 1

  • NYU Langone Health · New York, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.